Boji Medical Technology Co.,Ltd. (SHE:300404)
China · Delayed Price · Currency is CNY 10.82
-0.32 (-2.87%)
At close: May 12, 2026
Boji Medical Technology Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 949.94 | 868.64 | 723.92 | 541.59 | 411.06 | 314.65 |
Other Revenue | - | - | 18.1 | 14.24 | 12.62 | 9.55 |
| 949.94 | 868.64 | 742.02 | 555.83 | 423.68 | 324.2 | |
Revenue Growth (YoY) | 33.15% | 17.07% | 33.50% | 31.19% | 30.69% | 24.47% |
Cost of Revenue | 694.18 | 633.03 | 517.98 | 373.34 | 267.57 | 185.56 |
Gross Profit | 255.76 | 235.62 | 224.04 | 182.49 | 156.11 | 138.64 |
Selling, General & Admin | 122.99 | 123.56 | 124.44 | 108.99 | 88.65 | 71.19 |
Research & Development | 60.11 | 57.5 | 62.59 | 54.97 | 43.68 | 27.65 |
Other Operating Expenses | -3.83 | -5.49 | 6.62 | 3.24 | 2.8 | 2.27 |
Operating Expenses | 179.26 | 175.56 | 214.03 | 182.56 | 150.05 | 109.43 |
Operating Income | 76.5 | 60.05 | 10 | -0.07 | 6.06 | 29.22 |
Interest Expense | - | - | -3.19 | -1.53 | -0.7 | -1.41 |
Interest & Investment Income | 1.22 | 0.84 | 4.28 | 4.33 | 3.64 | 4.21 |
Currency Exchange Gain (Loss) | - | - | 0 | -0.01 | -0.01 | -0.01 |
Other Non Operating Income (Expenses) | -24.48 | -22.11 | -2.34 | -0.59 | -0.41 | -0.4 |
EBT Excluding Unusual Items | 53.24 | 38.79 | 8.76 | 2.12 | 8.58 | 31.61 |
Gain (Loss) on Sale of Investments | 1.83 | 1.48 | 1.06 | 0.59 | 1.79 | - |
Gain (Loss) on Sale of Assets | - | - | -0.21 | 0 | - | - |
Asset Writedown | -9.17 | -10.21 | -0.08 | -0.03 | -0.07 | -0.3 |
Other Unusual Items | - | - | 8.89 | 14.95 | 14.27 | 15.78 |
Pretax Income | 45.89 | 30.06 | 18.42 | 17.63 | 24.57 | 47.09 |
Income Tax Expense | 1.59 | -2.85 | -12.24 | -9.56 | -4.74 | 3.59 |
Earnings From Continuing Operations | 44.3 | 32.91 | 30.66 | 27.19 | 29.31 | 43.5 |
Minority Interest in Earnings | -1.24 | -2.42 | -1.88 | -2.85 | -1.64 | -4.62 |
Net Income | 43.05 | 30.49 | 28.78 | 24.34 | 27.67 | 38.88 |
Net Income to Common | 43.05 | 30.49 | 28.78 | 24.34 | 27.67 | 38.88 |
Net Income Growth | 166.36% | 5.97% | 18.23% | -12.04% | -28.84% | 128.87% |
Shares Outstanding (Basic) | 384 | 384 | 382 | 370 | 367 | 349 |
Shares Outstanding (Diluted) | 384 | 384 | 383 | 371 | 367 | 349 |
Shares Change (YoY) | 0.38% | 0.36% | 3.14% | 0.97% | 5.18% | 10.02% |
EPS (Basic) | 0.11 | 0.08 | 0.08 | 0.07 | 0.08 | 0.11 |
EPS (Diluted) | 0.11 | 0.08 | 0.08 | 0.07 | 0.08 | 0.11 |
EPS Growth | 165.35% | 5.58% | 14.63% | -12.88% | -32.34% | 108.04% |
Free Cash Flow | 49.2 | 68.3 | -2.57 | -26.24 | -89.59 | -23.89 |
Free Cash Flow Per Share | 0.13 | 0.18 | -0.01 | -0.07 | -0.24 | -0.07 |
Dividend Per Share | - | - | 0.012 | 0.010 | 0.010 | 0.014 |
Dividend Growth | - | - | 20.00% | - | -30.07% | - |
Gross Margin | 26.92% | 27.13% | 30.19% | 32.83% | 36.85% | 42.77% |
Operating Margin | 8.05% | 6.91% | 1.35% | -0.01% | 1.43% | 9.01% |
Profit Margin | 4.53% | 3.51% | 3.88% | 4.38% | 6.53% | 11.99% |
Free Cash Flow Margin | 5.18% | 7.86% | -0.35% | -4.72% | -21.15% | -7.37% |
EBITDA | 103.17 | 86.21 | 34.07 | 20.4 | 24.99 | 46.03 |
EBITDA Margin | 10.86% | 9.93% | 4.59% | 3.67% | 5.90% | 14.20% |
D&A For EBITDA | 26.68 | 26.16 | 24.07 | 20.47 | 18.93 | 16.81 |
EBIT | 76.5 | 60.05 | 10 | -0.07 | 6.06 | 29.22 |
EBIT Margin | 8.05% | 6.91% | 1.35% | -0.01% | 1.43% | 9.01% |
Effective Tax Rate | 3.47% | - | - | - | - | 7.62% |
Revenue as Reported | - | - | 742.02 | 555.83 | 423.68 | 324.2 |
Advertising Expenses | - | - | 2.29 | 1.85 | 0.71 | 0.65 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.